UBS Group
BPMC

UBS Group’s Blueprint Medicines BPMC Stock Holding History

UBS Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,167,028
Closed -$278M – 10355
2025
Q2 		$278M Buy
2,167,028
+1,953,223
+914% +$203M 0.05% 395
2025
Q1 		$18.9M Buy
213,805
+16,345
+8% +$1.59M ﹤0.01% 2386
2024
Q4 		$17.2M Buy
197,460
+79,904
+68% +$7.32M ﹤0.01% 2486
2024
Q3 		$10.9M Buy
117,556
+32,933
+39% +$3.27M ﹤0.01% 2283
2024
Q2 		$9.12M Sell
84,623
-40,812
-33% -$4.09M ﹤0.01% 2283
2024
Q1 		$11.9M Sell
125,435
-1,103
-0.9% -$94.6K ﹤0.01% 2129
2023
Q4 		$11.7M Buy
126,538
+61,486
+95% +$3.98M ﹤0.01% 1972
2023
Q3 		$3.27M Sell
65,052
-16,714
-20% -$893K ﹤0.01% 2976
2023
Q2 		$5.17M Sell
81,766
-2,907
-3% -$158K ﹤0.01% 2557
2023
Q1 		$3.81M Sell
84,673
-50,185
-37% -$2.26M ﹤0.01% 2785
2022
Q4 		$5.91M Buy
134,858
+125,458
+1,335% +$6.02M ﹤0.01% 2339
2022
Q3 		$619K Sell
9,400
-23,848
-72% -$1.53M ﹤0.01% 4153
2022
Q2 		$1.68M Sell
33,248
-15,055
-31% -$882K ﹤0.01% 3300
2022
Q1 		$3.09M Sell
48,303
-16,018
-25% -$1.15M ﹤0.01% 3034
2021
Q4 		$6.89M Buy
64,321
+11,617
+22% +$1.22M ﹤0.01% 2489
2021
Q3 		$5.42M Buy
52,704
+32,101
+156% +$2.99M ﹤0.01% 2585
2021
Q2 		$1.81M Sell
20,603
-44,510
-68% -$4.08M ﹤0.01% 3665
2021
Q1 		$6.33M Buy
65,113
+47,436
+268% +$4.74M ﹤0.01% 2370
2020
Q4 		$1.98M Buy
17,677
+12,178
+221% +$1.28M ﹤0.01% 3418
2020
Q3 		$510K Sell
5,499
-3,254
-37% -$251K ﹤0.01% 4179
2020
Q2 		$683K Buy
8,753
+4,687
+115% +$317K ﹤0.01% 3869
2020
Q1 		$238K Sell
4,066
-20,300
-83% -$1.31M ﹤0.01% 4587
2019
Q4 		$1.95M Sell
24,366
-35,564
-59% -$2.66M ﹤0.01% 3564
2019
Q3 		$4.4M Buy
59,930
+59,370
+10,602% +$5.13M ﹤0.01% 2507
2019
Q2 		$53K Buy
560
+225
+67% +$18.6K ﹤0.01% 5867
2019
Q1 		$27K Sell
335
-33,799
-99% -$2.5M ﹤0.01% 6029
2018
Q4 		$1.84M Buy
34,134
+11,288
+49% +$686K ﹤0.01% 3120
2018
Q3 		$1.78M Buy
22,846
+22,456
+5,758% +$1.56M ﹤0.01% 3325
2018
Q2 		$25K Sell
390
-56,428
-99% -$4.49M ﹤0.01% 6531
2018
Q1 		$5.21M Buy
56,818
+39,774
+233% +$3.43M ﹤0.01% 2270
2017
Q4 		$1.28M Sell
17,044
-16,391
-49% -$1.15M ﹤0.01% 3563
2017
Q3 		$2.33M Buy
33,435
+10,594
+46% +$566K ﹤0.01% 2990
2017
Q2 		$1.16M Buy
22,841
+15,513
+212% +$659K ﹤0.01% 3489
2017
Q1 		$293K Sell
7,328
-5,501
-43% -$197K ﹤0.01% 4405
2016
Q4 		$360K Buy
12,829
+9,514
+287% +$287K ﹤0.01% 4358
2016
Q3 		$98K Buy
3,315
+415
+14% +$10.3K ﹤0.01% 5003
2016
Q2 		$58K Sell
2,900
-5,901
-67% -$107K ﹤0.01% 5407
2016
Q1 		$158K Buy
8,801
+329
+4% +$5.71K ﹤0.01% 4657
2015
Q4 		$223K Buy
8,472
+121
+1% +$2.72K ﹤0.01% 4581
2015
Q3 		$178K Buy
8,351
+526
+7% +$14.5K ﹤0.01% 4726
2015
Q2 		$207K Buy
+7,825
New +$223K ﹤0.01% 4838

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS Group's BPMC Position: Q3 2025 in Review

UBS Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 2,167,028 shares — an estimated $278M sold.

UBS Group first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $278M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • UBS Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • UBS Group sold 2,167,028 Blueprint Medicines shares in Q3 2025, an estimated $278M.
  • UBS Group first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
  • UBS Group's Blueprint Medicines position peaked at $278M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.